WYE-125132 Size:2mg solid and in engineered cells overexpressing

and in engineered cells overexpressing oncogenic RAS

Y27632 dihydrochloride

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26

WO 2018057618 A1

PubMed Central PMCID: PMC4275380

WYE-125132 Size:2mg solid and in engineered cells overexpressingWYE 125132, also known as WYE 132, is a highly potent, ATP competitive, and specific mTOR kinase inhibitor (IC(50): 0. 19 + 0. 07 nmol L; >5, 000 fold selective versus PI3Ks). WYE 132 inhibited mTORC1 and mTORC2 in diverse cancer models in vitro and in vivo. Importantly, consistent with genetic ablation of mTORC2, WYE 132 targeted P AKT(S473) and AKT function without significantly reducing the steady state level of the PI3K PDK1 activity biomarker P